• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

作者信息

Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G

机构信息

1] Hematology Unit, Department of Medical Sciences, University of Cagliari, Cagliari, Italy [2] Bone Marrow Transplant Center, R. Binaghi Hospital, Cagliari, Italy.

Hematology Unit, Department of Medical Sciences, University of Cagliari, Cagliari, Italy.

出版信息

Leukemia. 2014 Jan;28(1):225-7. doi: 10.1038/leu.2013.235. Epub 2013 Aug 9.

DOI:10.1038/leu.2013.235
PMID:23929216
Abstract
摘要

相似文献

1
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.鲁索替尼治疗骨髓纤维化患者后乙肝病毒感染再激活
Leukemia. 2014 Jan;28(1):225-7. doi: 10.1038/leu.2013.235. Epub 2013 Aug 9.
2
Hepatitis B virus reactivation associated with ruxolitinib.与芦可替尼相关的乙型肝炎病毒再激活
Ann Hematol. 2014 Jun;93(6):1075-6. doi: 10.1007/s00277-013-1936-5. Epub 2013 Oct 31.
3
Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.一名原发性骨髓纤维化患者在接受鲁索替尼治疗后发生肺结核复发。
Leuk Lymphoma. 2015 May;56(5):1528-9. doi: 10.3109/10428194.2014.963082. Epub 2014 Nov 5.
4
[Ruxolitinib prescription in myelofibrosis].[芦可替尼在骨髓纤维化中的处方]
Bull Cancer. 2013 Sep;100(9):897-902. doi: 10.1684/bdc.2013.1792.
5
Klebsiella pneumoniae primary liver abscess associated with ruxolitinib.与鲁索替尼相关的肺炎克雷伯菌原发性肝脓肿
Ann Hematol. 2016 Sep;95(9):1561-2. doi: 10.1007/s00277-016-2718-7. Epub 2016 Jun 4.
6
Ruxolitinib (Jakafi) for myelofibrosis.芦可替尼（捷恪卫）用于治疗骨髓纤维化。
Med Lett Drugs Ther. 2012 Apr 2;54(1387):27-8.
7
Ruxolitinib for myelofibrosis therapy: current context, pros and cons.芦可替尼用于骨髓纤维化治疗：当前情况、利弊
Leukemia. 2012 Jul;26(7):1449-51. doi: 10.1038/leu.2012.21.
8
Long-term outcome of treatment with ruxolitinib in myelofibrosis.芦可替尼治疗骨髓纤维化的长期疗效
N Engl J Med. 2011 Oct 13;365(15):1455-7. doi: 10.1056/NEJMc1109555.
9
Ruxolitinib.鲁索替尼
Nat Rev Drug Discov. 2012 Feb 1;11(2):103-4. doi: 10.1038/nrd3652.
10
Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib.五例接受芦可替尼治疗的真性红细胞增多症后骨髓纤维化患者的临床和形态学特征。
Ann Hematol. 2015 Oct;94(10):1749-51. doi: 10.1007/s00277-015-2429-5. Epub 2015 Jun 18.

引用本文的文献

1
Ruxolitinib and Hepatitis-B Virus Reactivation: A Clinical Concern Requiring Prophylactic Management.芦可替尼与乙型肝炎病毒再激活：一项需要预防性管理的临床关注问题。
Pak J Med Sci. 2025 Jul;41(7):2164. doi: 10.12669/pjms.41.7.12301.
2
Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.芦可替尼治疗的骨髓纤维化患者血细胞减少和感染的真实世界管理
EJHaem. 2025 Mar 21;6(2):e70007. doi: 10.1002/jha2.70007. eCollection 2025 Apr.
3
Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.

本文引用的文献

1
Mutations and prognosis in primary myelofibrosis.原发性骨髓纤维化中的突变与预后。
Leukemia. 2013 Sep;27(9):1861-9. doi: 10.1038/leu.2013.119. Epub 2013 Apr 26.
2
Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy.免疫调节全身化疗后肝炎病毒再激活。
Hepatol Res. 2013 Feb;43(2):113-21. doi: 10.1111/hepr.12014. Epub 2012 Nov 27.
3
Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy.含利妥昔单抗化疗方案治疗 B 细胞淋巴瘤时预防性应用拉米夫定预防乙型肝炎病毒再激活的疗效。
接受鲁索替尼治疗的骨髓增殖性肿瘤患者发生乙型肝炎病毒再激活的风险。
World J Hepatol. 2023 Nov 27;15(11):1188-1195. doi: 10.4254/wjh.v15.i11.1188.
4
Tofacitinib treatment of rheumatoid arthritis increases senescent T cell frequency in patients and limits T cell function in vitro.托法替尼治疗类风湿关节炎增加患者衰老 T 细胞频率并限制体外 T 细胞功能。
Eur J Immunol. 2023 Aug;53(8):e2250353. doi: 10.1002/eji.202250353. Epub 2023 May 31.
5
Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature.JAK抑制剂对患有信号转导和转录激活因子1功能获得性（GOF）突变的儿科患者的影响——10例儿童病例及文献综述
J Clin Immunol. 2022 Jul;42(5):1071-1082. doi: 10.1007/s10875-022-01257-x. Epub 2022 Apr 29.
6
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.JAK抑制剂在骨髓增殖性肿瘤中的作用：当前观点与展望
Int J Hematol. 2022 May;115(5):626-644. doi: 10.1007/s12185-022-03335-7. Epub 2022 Mar 29.
7
Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors.接受 JAK 抑制剂治疗的 MPN 患者的免疫失调和感染并发症。
Front Immunol. 2021 Nov 19;12:750346. doi: 10.3389/fimmu.2021.750346. eCollection 2021.
8
Adverse Effects of Immunosuppression: Infections.免疫抑制的不良反应：感染。
Handb Exp Pharmacol. 2022;272:287-314. doi: 10.1007/164_2021_550.
9
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.新冠疫情期间的费城染色体阴性慢性骨髓增殖性肿瘤：挑战与未来展望
Cancers (Basel). 2021 Sep 23;13(19):4750. doi: 10.3390/cancers13194750.
10
The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy.BCR-ABL 阴性骨髓增殖性肿瘤中的免疫景观：炎症、感染和免疫治疗机会。
Br J Haematol. 2022 Mar;196(5):1149-1158. doi: 10.1111/bjh.17850. Epub 2021 Oct 7.
Support Care Cancer. 2013 May;21(5):1265-71. doi: 10.1007/s00520-012-1656-8. Epub 2012 Nov 15.
4
Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.1例接受JAK2选择性抑制剂治疗患者的播散性结核病：病例报告
BMC Res Notes. 2012 Oct 5;5:552. doi: 10.1186/1756-0500-5-552.
5
Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment.γ-干扰素和肿瘤坏死因子-α 对拉米夫定治疗后乙型肝炎病毒的影响。
World J Gastroenterol. 2012 Jul 21;18(27):3617-22. doi: 10.3748/wjg.v18.i27.3617.
6
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.芦可替尼治疗骨髓纤维化的双盲、安慰剂对照试验。
N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.
7
Ruxolitinib for myelofibrosis therapy: current context, pros and cons.芦可替尼用于骨髓纤维化治疗：当前情况、利弊
Leukemia. 2012 Jul;26(7):1449-51. doi: 10.1038/leu.2012.21.
8
The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection.细胞介导的免疫反应特征可识别隐匿性乙型肝炎病毒感染的不同模式。
Gastroenterology. 2008 May;134(5):1470-81. doi: 10.1053/j.gastro.2008.02.017. Epub 2008 Feb 14.
9
Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA.肿瘤坏死因子激活一种针对乙肝病毒的保守性固有抗病毒反应，这种反应会使核衣壳不稳定并减少细胞核内的病毒DNA。
J Virol. 2007 Jul;81(14):7351-62. doi: 10.1128/JVI.00554-07. Epub 2007 May 2.
10
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.抗癌治疗期间乙型肝炎病毒再激活的诊断、预防及管理
Hepatology. 2006 Feb;43(2):209-20. doi: 10.1002/hep.21051.